^
    8ms
    A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER) (clinicaltrials.gov)
    P1, N=475, Recruiting, Tesaro, Inc. | Trial completion date: Jul 2025 --> Apr 2027 | Trial primary completion date: Dec 2024 --> Apr 2025
    Trial completion date • Trial primary completion date • Metastases
    |
    Opdivo (nivolumab) • cisplatin • carboplatin • docetaxel • pemetrexed • Jemperli (dostarlimab-gxly) • cobolimab (TSR-022) • encelimab (TSR-033)
    9ms
    A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER) (clinicaltrials.gov)
    P1, N=475, Recruiting, GlaxoSmithKline
    New P1 trial • Metastases
    |
    Opdivo (nivolumab) • cisplatin • carboplatin • docetaxel • pemetrexed • Jemperli (dostarlimab-gxly) • cobolimab (TSR-022) • encelimab (TSR-033)
    over1year
    CITRINO: Study of TSR-033 With an Anti-programmed Cell Death-1 Receptor (PD-1) in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=111, Completed, Tesaro, Inc. | Active, not recruiting --> Completed | Trial completion date: Nov 2022 --> Feb 2023 | Trial primary completion date: Nov 2022 --> Jun 2022
    Trial completion • Trial completion date • Trial primary completion date
    |
    RAS wild-type
    |
    Avastin (bevacizumab) • 5-fluorouracil • oxaliplatin • irinotecan • Jemperli (dostarlimab-gxly) • leucovorin calcium • encelimab (TSR-033)
    4years
    Quantifying the efficacy of checkpoint inhibitors on CD8 cytotoxic T cells for immunotherapeutic applications via single-cell interaction. (PubMed, Cell Death Dis)
    We also found that the combination of TSR-042 and TSR-033 appears to synergistically increase tumor cell killing and the single-cell level. This study provides a novel single-cell-based assessment of the impact these checkpoint inhibitors have on cellular interactions with CD8 T cells.
    Clinical • Journal • Checkpoint inhibition
    |
    LAG3 (Lymphocyte Activating 3)
    |
    Jemperli (dostarlimab-gxly) • encelimab (TSR-033)
    over4years
    A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER) (clinicaltrials.gov)
    P1, N=369, Recruiting, Tesaro, Inc. | Trial primary completion date: Apr 2022 --> Jul 2021
    Clinical • Trial primary completion date • PD(L)-1 Biomarker
    |
    CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)
    |
    Opdivo (nivolumab) • cisplatin • docetaxel • Jemperli (dostarlimab-gxly) • cobolimab (TSR-022) • encelimab (TSR-033)
    over4years
    A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER) (clinicaltrials.gov)
    P1, N=369, Recruiting, Tesaro, Inc. | Trial primary completion date: Jul 2021 --> Apr 2022
    Clinical • Trial primary completion date • PD(L)-1 Biomarker
    |
    CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)
    |
    Opdivo (nivolumab) • cisplatin • docetaxel • Jemperli (dostarlimab-gxly) • cobolimab (TSR-022) • encelimab (TSR-033)